2^nd POSTGRADUATE

Lymphoma Conference

Thursday, March 17, 2016

Session I: Hodgkin Lymphoma

Chairmen: A.M. Carella, P.L. Zinzani

The "PET world"

S.F. Barrington

Salvage treatment with Brentuximab Vedotin as a single agent and in combination with Bendamustine

C.H. Moskowitz

Update on the role of anti-PD1 and anti-PD-L1

S.M. Ansell

News on allogeneic transplantation:

BV after Allo

T. Illidge

News on allogeneic transplantation:

Anti-PD1 after allo

S.M. Ansell

Session II: T-cell lymphoma

Chairmen: S.A. Pileri, P.L. Zinzani

Different front-line treatments related to the histologic subtypes in PTCL: is it possible today?

S.M. Horwitz

Should ASCT in 1st remission be the standard of care for patients with PTCL?

Against

B. Pro

Should ASCT in 1st remission be the standard of care for patients with PTCL?

Pro

F. D'Amore

New agents in:

PTCL

B. Pro

New agents in:

CTCL

Y.H. Kim

Friday, March 18, 2016

Session III: Follicular Lymphoma

Chairmen: B.D. Cheson, O.A. O'Connor

Microenvironment modulation as a therapeutic strategy

H.G. Wendel

Novel Targets/Therapies:

BTK inhibitors

B.D. Cheson

Novel Targets/Therapies:

PI3K inhibitors

A. Younes

Novel Targets/Therapies:

BCL-2 inhibitors

J. Friedberg

Novel Targets/Therapies:

Proteasome inhibitors

O.A. O'Connor

The new concept of chemotherapy-free treatment regimens

B.D. Cheson

Session IV: Diffuse Large B-Cell Lymphoma

Chairman: A. Younes

Update on the treatment of "Grey Zone" lymphomas: conventional and innovative therapeutic approaches

W.H. Wilson

Is there a role for Brentuximab Vedotin in the treatment of DLBCL?

S.M. Ansell